Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
somatropin + metformin
- Development stage
- Unknown
- Lead developer
- Cambridge University Hospitals
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
This therapeutic approach involves the combination of recombinant human growth hormone (somatropin) and the insulin-sensitizing agent metformin. It is being investigated in a clinical trial (NCT02931591) sponsored by Cambridge University Hospitals NHS Foundation Trust, specifically for children born small for gestational age (SGA) who exhibit short stature. The study, led by Professor David Dunger and Dr. Ajay Thankamony, explores the hypothesis that insulin sensitivity is a key determinant of the growth response to growth hormone therapy. Somatropin acts as an agonist at the growth hormone receptor to stimulate the production of insulin-like growth factor-1 (IGF-1), while metformin is added to improve insulin sensitivity, potentially enhancing the IGF-1 response and improving overall growth outcomes in children with genetic predispositions to lower insulin sensitivity. The research is supported by an investigator-initiated grant from Merck KGaA.
- Other names
- growth hormone and metforminGH + metforminrecombinant human growth hormone and metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)GHR (Growth hormone receptor)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on somatropin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on somatropin + metformin.